We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $11.7B
1-Year Est. Return 174.13%
This Fund
S&P 500
This Quarter Est. Return
+27.09%
1 Year Est. Return
+174.13%
3 Year Est. Return
+466.81%
5 Year Est. Return
+622.69%
10 Year Est. Return
+19,772.83%
AUM
$11.7B
AUM Growth
+$1.66B
Cap. Flow
-$50.3M
Cap. Flow %
-0.43%
Top 10 Hldgs %
47.72%
Holding
97
New
9
Increased
26
Reduced
8
Closed
13

Top Buys

Rank Stock Value
1
KLRA
Kailera Therapeutics
KLRA
+$237M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$103M
3
CGON icon
CG Oncology
CGON
+$100M
4
ORKA
Oruka Therapeutics
ORKA
+$72M
5
GPCR icon
Structure Therapeutics
GPCR
+$71.1M

Top Sells

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$234M
2
APLS
Apellis Pharmaceuticals
APLS
+$148M
3
COGT icon
Cogent Biosciences
COGT
+$110M
4
ISRG icon
Intuitive Surgical
ISRG
+$101M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$81.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.93%
2 Financials 0.07%
3 Miscellaneous 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
URGN icon
26
UroGen Pharma
URGN
$2.13B
$167M 1.43%
4,543,895
– –
GHRS icon
27
GH Research
GHRS
$1.92B
$160M 1.36%
5,933,815
– –
IMCR icon
28
Immunocore
IMCR
$1.89B
$155M 1.32%
4,869,798
– –
CMPS
29
Compass Pathways
CMPS
$1.9B
$151M 1.29%
10,700,974
+68,584
+0.6% +$696K
IMTX icon
30
Immatics
IMTX
$1.44B
$131M 1.12%
12,946,176
+76,836
+0.6% +$812K
ZLAB icon
31
Zai Lab
ZLAB
$2.93B
$125M 1.07%
6,574,032
– –
IMVT icon
32
Immunovant
IMVT
$8.51B
$122M 1.05%
3,177,849
– –
BLTE
33
Belite Bio
BLTE
$6.11B
$110M 0.94%
715,332
– –
XNCR icon
34
Xencor
XNCR
$1.94B
$109M 0.93%
6,777,461
– –
TSHA icon
35
Taysha Gene Therapies
TSHA
$1.88B
$92.3M 0.79%
13,560,258
-119,990
-0.9% -$710K
COGT icon
36
Cogent Biosciences
COGT
$6.02B
$89.4M 0.76%
2,309,021
-3,149,654
-58% -$110M
ALKS icon
37
Alkermes
ALKS
$7.95B
$87.6M 0.75%
1,672,356
– –
GPCR icon
38
Structure Therapeutics
GPCR
$3.38B
$86.3M 0.74%
+1,607,507
New +$71.1M
REPL icon
39
Replimune Group
REPL
$1.46B
$82M 0.7%
7,411,581
+54,665
+0.7% +$334K
CSTL icon
40
Castle Biosciences
CSTL
$1.02B
$66.3M 0.57%
2,778,335
+20,000
+0.7% +$445K
CADL icon
41
Candel Therapeutics
CADL
$1B
$66.1M 0.56%
6,422,018
– –
RCKT icon
42
Rocket Pharmaceuticals
RCKT
$424M
$60.5M 0.52%
17,687,772
– –
KOD icon
43
Kodiak Sciences
KOD
$2.37B
$58M 0.49%
1,487,934
– –
AKTS
44
Aktis Oncology
AKTS
$1.43B
$51.3M 0.44%
1,592,043
– –
AXGN icon
45
Axogen
AXGN
$2.77B
$46.7M 0.4%
+1,011,576
New +$40.8M
DHR icon
46
Danaher
DHR
$152B
$43.8M 0.37%
+230,000
New +$41.8M
CGEM icon
47
Cullinan Oncology
CGEM
$1.4B
$43.1M 0.37%
2,364,347
+658,387
+39% +$9.78M
NGNE icon
48
Neurogene
NGNE
$732M
$42.8M 0.37%
1,362,456
– –
HNGE
49
Hinge Health
HNGE
$7.05B
$41.5M 0.35%
500,000
-1,430,000
-74% -$77.6M
OBIO icon
50
Orchestra BioMed
OBIO
$311M
$41.2M 0.35%
9,556,063
+1,250,000
+15% +$5.11M
1
2
3 4

Similar funds

CIM
Centersquare Investment Management Conshohocken, Pennsylvania $11.7B AUM 20.39% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
UE
Unisphere Establishment Vaduz, Liechtenstein $11.7B AUM 0.31% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $11.8B AUM 25.68% 1-Year Est. Return
CCMT
CMT Capital Markets Trading Frankfurt, Germany $11.8B AUM 39.43% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

RTW Investments's Q2 2026 Portfolio in Review

As of Q2 2026, RTW Investments held 97 positions worth $11.7B, up 17% from $10B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

RTW Investments's Q2 2026 filing shows 9 new, 26 increased, 8 reduced and 13 closed positions. Its largest new stake was Kailera Therapeutics: 10,776,820 shares worth $237M. The largest sale was Apogee Therapeutics, an estimated $234M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials and Miscellaneous.

  • RTW Investments's largest Q2 2026 buy was Kailera Therapeutics: 10,776,820 shares worth $237M.
  • RTW Investments added most to Ultragenyx Pharmaceutical in Q2 2026, an estimated $103M increase.
  • RTW Investments's biggest Q2 2026 reduction was Cogent Biosciences, cutting an estimated $110M.
  • RTW Investments fully exited Apogee Therapeutics in Q2 2026, selling an estimated $234M.
  • RTW Investments's ten largest holdings make up 48% of its $11.7B portfolio in Q2 2026.
  • RTW Investments opened 9 new positions and closed 13 in Q2 2026.
  • RTW Investments's portfolio value rose 17% quarter-over-quarter to $11.7B.

Based on RTW Investments's 13F filing for Q2 2026, filed 14 Aug 2026.